The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06879041




Registration number
Help: Registration number
NCT06879041
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
11/03/2025
Date registered
Help: Date registered
17/03/2025
Date last updated
Help: Date last updated
16/10/2026

Titles & IDs
Public title
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Scientific title
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Additional trial identifiers [1] 0 0
D7580C00001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Metastatic Castration-Resistant Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - AZD2287
Treatment: Drugs - AZD2275
Treatment: Drugs - AZD2284

Experimental: Part A: Cohort A1: AZD2287 (Hot only) - Participants will receive AZD2287. If eligible for treatment, will receive dose level (DL)1 of AZD2284.

Experimental: Part A: Cohort A2: AZD2275 + AZD2287 (Cold +Hot) - Participants will receive DL1 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.

Experimental: Part A: Cohort A3: AZD2275 + AZD2287 (Cold +Hot) - Participants will receive DL2 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.

Experimental: Part B (Actinium-225 Dose Escalation): DL1: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL1 of AZD2284.

Experimental: Part B (Actinium-225 Dose Escalation): DL2: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL2 of AZD2284.

Experimental: Part B (Actinium-225 Dose Escalation): DL3: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL3 of AZD2284.

Experimental: Part B (Actinium-225 Dose Escalation): DL4: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL4 of AZD2284.

Experimental: Part B: Cohort E1 - Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.

Experimental: Part B: Cohort E2 - Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.


Treatment: Drugs: AZD2287
Participants will receive AZD2287

Treatment: Drugs: AZD2275
Participants will receive AZD2275

Treatment: Drugs: AZD2284
Participants will receive AZD2284

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with adverse event (AEs)
Timepoint [1] 0 0
Part A: Up to Day 28; Part B: Up to 5 years
Primary outcome [2] 0 0
Number of participants with Dose Limiting Toxicities (DLTs)
Timepoint [2] 0 0
Part B: Up to 84 days of receiving AZD2284
Primary outcome [3] 0 0
Estimates of residence time
Timepoint [3] 0 0
Part A: Up to 8 days after a dose of AZD2287
Primary outcome [4] 0 0
Absorbed radiation doses for AZD2287 and AZD2284
Timepoint [4] 0 0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Primary outcome [5] 0 0
Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275
Timepoint [5] 0 0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Primary outcome [6] 0 0
Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar images
Timepoint [6] 0 0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Secondary outcome [1] 0 0
Overall Response Rate (ORR)
Timepoint [1] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [2] 0 0
Proportion of participants with Prostate-Specific Antigen (PSA) 50
Timepoint [2] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [3] 0 0
Proportion of participants with PSA90
Timepoint [3] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [4] 0 0
Time to PSA50 response
Timepoint [4] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [5] 0 0
Duration of Response (DoR)
Timepoint [5] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [6] 0 0
Radiographic Progression Free Survival (rPFS)
Timepoint [6] 0 0
Up to 12 months after the last dose of AZD2284
Secondary outcome [7] 0 0
Overall Survival (OS)
Timepoint [7] 0 0
Part A: Up to Day 28; Part B: Up to 5 years
Secondary outcome [8] 0 0
Pharmacokinetic Clearance
Timepoint [8] 0 0
Part A: Up to Day 28; Part B: Up to 84 days
Secondary outcome [9] 0 0
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
Timepoint [9] 0 0
Part A: Up to Day 28; Part B: Up to 84 days
Secondary outcome [10] 0 0
Maximum observed drug concentration (Cmax)
Timepoint [10] 0 0
Part A: Up to Day 28; Part B: Up to 84 days
Secondary outcome [11] 0 0
Half-life (t1/2)
Timepoint [11] 0 0
Part A: Up to Day 28; Part B: Up to 84 days
Secondary outcome [12] 0 0
Changes in plasma concentrations of AZD2287 and AZD2284 following AZD2275 pre-administration compared to AZD2287 and AZD2284 alone
Timepoint [12] 0 0
Part A: Up to Day 28; Part B: Up to 84 days
Secondary outcome [13] 0 0
Number of participants with positive antidrug antibodies (ADAs)
Timepoint [13] 0 0
Part A: Up to Day 28; Part B: Approximately 28 days after End of Treatment (EOT) visit

Eligibility
Key inclusion criteria
* eria:
* • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* • Histologically confirmed diagnosis of adenocarcinoma of the prostate without strong clinical suspicion of majority neuroendocrine differentiation.
* • Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
* • At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained = 28 days prior to the first dose of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases.
* • Adequate organ function
* • Part A only: Metastatic prostate cancer considered to be stable or progressing metastatic castration resistant prostate cancer (mCRPC).
* • Part B only: Progressing mCRPC defined as meeting at least one of following documented criteria -
* a)Serum/plasma PSA progression
* b)Soft-tissue progression
* c)Progression of bone disease
* • Part B Dose Escalation: Previously treated with at least 2 prior lines of systemic anti-cancer therapy for mCRPC. Prior lines must include:
* a)At least 1 androgen receptor pathway inhibitor (ARPI)
* b)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
* c)A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) = 10 mut/Mb
* • Part B Dose Expansion: Previously treated with at least 1 prior line of systemic anti-cancer therapy for mCRPC. Prior lines must include:
* (a)At least 1 ARPI
* (b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision.
* (c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB = 10 mut/Mb.
* (d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
* (e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a prior line of systemic therapy.
* Main
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
* • Treatment with any radiopharmaceutical within 6 weeks of the first dose of Investigational Medicinal Product (IMP).
* • Radiation therapy (RT) or external beam radiation therapy (EBRT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade = 1.
* • Administration of any systemic cytotoxic or investigational therapy = 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.
* • All prior treatment-related adverse events must have resolved to Grade = 1.
* • Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements.
* • Known or suspected allergies or contraindications to any of the investigational drugs or any component of the investigational drug formulation.
* • Clinically relevant proteinuria
* • Diffuse and intense osseous radiotracer uptake on bone scintigraphy or PSMA imaging characteristic of a superscan.
* • Chronic corticosteroid use greater than 10 mg prednisone equivalent daily.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
South Africa
State/province [11] 0 0
CapeTown
Country [12] 0 0
South Africa
State/province [12] 0 0
Durban
Country [13] 0 0
South Africa
State/province [13] 0 0
Pretoria

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Parexel
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicatesthat AZ are accepting requests for IPD, but this does not mean all requests will be approved.
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Available to whom?
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.